The Eli Lilly stock price fell as much as 4.8% this morning (Wednesday) after the company released new trial results on its Alzheimer's drug solanezumab.
Eli Lilly and Co. (NYSE: LLY) officials released data from a follow-up study on two of the drug's earlier trials. The Alzheimer's drug fell short of its goals in the first two trials, but the new data showed encouraging signs.
The Eli Lilly stock price fell as much as 4.8% this morning (Wednesday) after the company released new trial results on its Alzheimer's drug solanezumab.
Eli Lilly and Co. (NYSE: LLY) officials released data from a follow-up study on two of the drug's earlier trials. The Alzheimer's drug fell short of its goals in the first two trials, but the new data showed encouraging signs.
Here's everything investors need to know now...
